Business Context and Reporting Period
Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 28, 2024
Reporting Period: Event-based report regarding clinical trial progress.
Key Financial Metrics
This filing is a regulatory disclosure regarding operational milestones and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Operational Updates
The Company announced the finalization of agreements with all six planned site enrollment locations for the Phase 2 clinical trial of Ropidoxuridine for the treatment of glioblastoma. The confirmed sites include:
- Georgetown University Medical Center
- UNC Medical Center
- UVA Cancer Center
- John Theurer Cancer Center at Hackensack University Medical Center
- Allegheny Health Network (AHN) Cancer Institute
- Miami Cancer Institute (part of Baptist Health South Florida)
Patient screening for enrollment in the trial is currently underway.
Guidance, Outlook, and Risks
Outlook: Management indicates that the trial is moving forward with patient screening active across all sites.
Risks and Forward-Looking Statements: The filing contains forward-looking statements regarding future results, strategy, and plans. These statements are subject to known and unknown risks, uncertainties, and assumptions that may cause actual results to differ materially from expectations. The Company undertakes no obligation to update these statements except as required by law.
Investor Verification Checklist
- Verify the status of patient enrollment and screening progress at the six announced sites.
- Review the full text of the press release (Exhibit 99.1) for specific timelines regarding trial initiation.
- Monitor upcoming periodic reports (10-Q/10-K) for financial impact related to the Phase 2 trial costs.
- Assess the Company's cash runway given the operational expansion of the clinical trial.